[THE INVESTOR] On Sept. 28, Neopharm (092730) increased 6.5% to 34,400 won (US$31.37). It had declined 2.64% through the past month. Standard deviation, which indicates variableness, records 2.2% over the same period of time over one month.

Compared with its close competitors within the same industry, KOSDAQ, since the monthly volatility of Neopharm was the lowest, the earnings rate over one month was also relatively lower than that of its peer group. Over the recent month, the return-on-risk, the return on investment with consideration about risk, was -1.1%. Though the volatility was the lowest among its peer group, the return-on-risk was low as stock price decline. Moreover, compared with the KOSDAQ industry, the return-on-risk is below the industrial mean, 1.0, and thus it is hard to say that the industrial comparison performance was positive.

While institutions have been selling Neopharm during the past ten trading days, foreigners have been buying during the past two trading days. As a shareholding sum by investor group for the past four weeks, foreigners have bought 69,199 shares with a maintenance of shareholding. However, during the same period, institutions have sold 50,565 shares with a selling trend and individuals have sold 18,634 shares with a decreasing position.

Cumulated shareholdings per investor group (1Mo) Total shareholdings per investor group

By HeRo (hero@heraldcorp.com)

This article is produced by the algorithm developed by the artificial intelligence developer ThinkPool in collaboration with Herald Corp.